PAREXEL International Corporation (PRXL) Upgraded by Raymond James Financial, Inc. to Market Perform

PAREXEL International Corporation (NASDAQ:PRXL) was upgraded by research analysts at Raymond James Financial, Inc. from an “underperform” rating to a “market perform” rating in a research note issued to investors on Tuesday.

Several other equities analysts have also weighed in on PRXL. Mizuho initiated coverage on PAREXEL International Corporation in a research note on Thursday, March 23rd. They issued a “neutral” rating and a $86.00 target price on the stock. Zacks Investment Research raised PAREXEL International Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, April 5th. Evercore ISI raised PAREXEL International Corporation from an “in-line” rating to an “outperform” rating and set a $85.00 target price on the stock in a research note on Monday, May 15th. Barclays PLC reissued an “overweight” rating and issued a $87.00 target price on shares of PAREXEL International Corporation in a research note on Wednesday, May 17th. Finally, Goldman Sachs Group, Inc. (The) raised PAREXEL International Corporation from a “sell” rating to a “neutral” rating and increased their target price for the company from $63.00 to $77.00 in a research note on Tuesday, May 23rd. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $72.83.

Analyst Recommendations for PAREXEL International Corporation (NASDAQ:PRXL)

Shares of PAREXEL International Corporation (PRXL) traded up 3.90% during trading on Tuesday, hitting $87.19. 4,478,429 shares of the stock traded hands. PAREXEL International Corporation has a 52 week low of $51.16 and a 52 week high of $87.25. The firm’s 50-day moving average price is $78.07 and its 200-day moving average price is $68.38. The company has a market cap of $4.43 billion, a price-to-earnings ratio of 38.33 and a beta of 0.80.

PAREXEL International Corporation (NASDAQ:PRXL) last released its earnings results on Wednesday, May 3rd. The medical research company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.01. PAREXEL International Corporation had a return on equity of 28.68% and a net margin of 5.12%. The firm had revenue of $529.30 million for the quarter, compared to analyst estimates of $529.38 million. During the same quarter in the prior year, the firm posted $0.89 earnings per share. The company’s quarterly revenue was up .4% on a year-over-year basis. On average, equities research analysts anticipate that PAREXEL International Corporation will post $3.24 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2655248/parexel-international-corporation-prxl-upgraded-by-raymond-james-financial-inc-to-market-perform.html.

Large investors have recently made changes to their positions in the stock. Legato Capital Management LLC raised its stake in shares of PAREXEL International Corporation by 6,211.0% in the first quarter. Legato Capital Management LLC now owns 92,393 shares of the medical research company’s stock worth $1,464,000 after buying an additional 90,929 shares in the last quarter. Clinton Group Inc. purchased a new stake in shares of PAREXEL International Corporation during the first quarter worth about $3,682,000. Capstone Asset Management Co. raised its stake in shares of PAREXEL International Corporation by 3.8% in the first quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock worth $278,000 after buying an additional 160 shares in the last quarter. Macquarie Group Ltd. purchased a new stake in shares of PAREXEL International Corporation during the fourth quarter worth about $789,000. Finally, LSV Asset Management raised its stake in shares of PAREXEL International Corporation by 43.9% in the first quarter. LSV Asset Management now owns 380,751 shares of the medical research company’s stock worth $24,029,000 after buying an additional 116,200 shares in the last quarter. 97.69% of the stock is currently owned by institutional investors and hedge funds.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Receive News & Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.